FDA Accepts Immunome's NDA for Varegacestat in Desmoid Tumors

Key Facts

In a move reflecting significant progress in the biotechnology sector, Immunome announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for varegacestat. This oral gamma secretase inhibitor is designed to treat adults with desmoid tumors, a rare type of soft tissue tumor. The FDA has assigned a PDUFA target action date to determine the final approval of the treatment.

The acceptance follows the submission of clinical data supporting the drug's potential, positioning Immunome alongside peers like SpringWorks Therapeutics, which previously received approval for Ogsiveo in the same therapeutic area. Per market data, regulatory milestones of this nature are critical for mid-cap biotech firms as they transition from R&D stages toward commercial revenue generation.

Regarding market performance, IMNM closed at $23.9 (close July 6, 2026), having traded between a day low of $22.88 and a high of $24.3. While the upcoming economic calendar does not list immediate sector-specific catalysts, investors will focus on further FDA communications regarding the PDUFA timeline, with the recent low of $22.88 serving as a key technical level to watch.